A Phase 2 interventional study of AGN-151607-DP and Placebo for AGN-151607-DP in Ventral Hernia, sponsored by AbbVie. Recruiting at 13 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-25.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
A ventral hernia happens when the muscles in the front of your belly become weak and let organs push through, causing a bulge. If it gets worse, intestines can slip into the bulge, leading to serious pain and health problems. This study aims to asses if AGN-151607-DP is safe and effective for closing the belly wall after open ventral hernia surgery, without needing a complex procedure. Adverse Events and change in disease activity will be assessed.
AGN-151607-DP is an investigational drug being developed to treat ventral hernia. Participants will be randomly placed in treatment groups to receive either AGN151607-DP or matching placebo. Approximately 200 adult participants with midline ventral hernia needing open surgical repair will be enrolled in approximately 30 sites in the United States.
Participants will receive intramuscular injections of AGN-161607-DP or matching placebo on Day 1. Duration of the study is approximately 25 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
230 studies on the registry are indexed under Hernia, Ventral; 45 are open to participants now.
This study's planned enrollment of 200 is above the median of 90 across 153 interventional studies indexed under Hernia, Ventral.
Browse Hernia, Ventral studies →AbbVie is the lead sponsor of 973 studies on the registry; 133 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 214 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Midline ventral hernia requiring open surgical repair.
Exclusion Criteria:
Participants will receive AGN-151607-DP Dose A on Day 1.
Drug: AGN-151607-DP
Participants will receive AGN-151607-DP Dose B on Day 1.
Drug: AGN-151607-DP
Participants will receive AGN-151607-DP Dose C on Day 1.
Drug: AGN-151607-DP
Participants will receive Placebo for AGN-151607-DP on Day 1.
Drug: Placebo for AGN-151607-DP
Intramuscular Injection
Intramuscular Injection
Percentage of Participants Achieving Primary Fascial Closure (PFC) Without Use of Component Separation Technique (CST) in Open Ventral Hernia Surgical Repair
PFC will be defined as the ability to achieve fascia to fascia midline approximation.
Time frame: Up to approximately 1 Month
Percentage of Participants Experiencing Adverse Events
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Up to approximately 25 Months
Percentage of Participants Achieving PFC
PFC will be defined as the ability to achieve fascia to fascia midline approximation.
Time frame: Up to approximately 1 Month
Percentage of Participants With Usage of CST for the Purpose of PFC
Percentage of participants with usage of CST will be assessed.
Time frame: Up to approximately 1 Month
Number of Lateral Abdominal Wall Muscles Released to Achieve PFC
Number of lateral abdominal wall muscles released to achieve PFC will be assessed.
Time frame: Up to approximately 1 Month
Change From Baseline in Length of Lateral Abdominal Wall Complex as Measured by Abdominal CT Scan in Supine Position Prior to Surgical Repair
Change in length of lateral abdominal wall complex will be assessed.
Time frame: Up to approximately 1 Month
Change From Baseline in Length of Lateral Abdominal Wall Complex as Measured by Abdominal CT Scan Performing Valsalva Maneuver Prior to Surgical Repair
Change in length of lateral abdominal wall complex will be assessed.
Time frame: Up to approximately 1 Month
Change From Baseline in Width to the Hernia Defect as Measured by Abdominal CT Scan in Supine Position Prior to Surgical Repair
Change in width to the hernia defect will be assessed.
Time frame: Up to approximately 1 Month
Change From Baseline in Width to the Hernia Defect as Measured by Abdominal CT Scan Performing Valsalva Maneuver Prior to Surgical Repair
Change in width to the hernia defect will be assessed.
Time frame: Up to approximately 1 Month
Not enrolling at this site.
Not enrolling at this site.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan
Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Sep 2028, 31 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A